Circ Cardiovasc Qual
-
Circ Cardiovasc Qual · Mar 2015
Randomized Controlled TrialThe HEART Pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge.
The HEART Pathway is a decision aid designed to identify emergency department patients with acute chest pain for early discharge. No randomized trials have compared the HEART Pathway with usual care. ⋯ URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01665521.
-
Circ Cardiovasc Qual · Jan 2015
Randomized Controlled Trial Multicenter StudyEffect of a computer-guided, quality improvement program for cardiovascular disease risk management in primary health care: the treatment of cardiovascular risk using electronic decision support cluster-randomized trial.
Despite effective treatments to reduce cardiovascular disease risk, their translation into practice is limited. ⋯ https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336630. Australian New Zealand Clinical Trials Registry No. 12611000478910.
-
Circ Cardiovasc Qual · Jan 2015
Randomized Controlled Trial Multicenter StudyHospital variation in quality of discharge summaries for patients hospitalized with heart failure exacerbation.
Single-site studies have demonstrated inadequate quality of discharge summaries in timeliness, transmission, and content, potentially contributing to adverse outcomes. However, degree of hospital-level variation in discharge summary quality for patients hospitalized with heart failure (HF) is uncertain. ⋯ Even at the highest performing hospital, discharge summary quality is insufficient in terms of timeliness, transmission, and content. Improvements in all aspects of discharge summary quality are necessary to enable the discharge summary to serve as an effective transitional care tool.
-
Circ Cardiovasc Qual · Jan 2015
Randomized Controlled Trial Multicenter StudyAssociation of discharge summary quality with readmission risk for patients hospitalized with heart failure exacerbation.
-
Circ Cardiovasc Qual · Nov 2014
Randomized Controlled Trial Multicenter Study Observational StudyCulprit vessel versus multivessel intervention at the time of primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction and multivessel disease: real-world analysis of 3984 patients in London.
It is estimated that up to two thirds of patients presenting with ST-segment-elevation myocardial infarction have multivessel disease. The optimal strategy for treating nonculprit disease is currently under debate. This study provides a real-world analysis comparing a strategy of culprit-vessel intervention (CVI) versus multivessel intervention at the time of primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction. ⋯ In this observational analysis of patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, CVI was associated with increased survival at 1 year. Acknowledging the limitations with observational analyses, our findings support current recommended practice guidelines.